Clatterbridge was the first cancer research centre in the UK to give an injection of the Transgene experimental immunotherapy to a patient with ...

Non-small cell lung cancer (NSCLC) remains a predominant cause of cancer-related mortality worldwide. In recent years, immune checkpoint inhibitors (ICIs) have emerged as a transformative therapeutic ...

A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a ...

A novel test developed by Duke-NUS researchers enables real-time monitoring of T cells that have been engineered to ...

A breast cancer vaccine could be closer to reality, according to Cleveland Clinic, as its researchers have announced some encouraging results. Researchers and doctors weigh in.

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

UCSF researchers develop customizable SNIPR sensors that activate engineered cells only near tumors, promising precise cancer ...

The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

In a small subset of those patients, the combination resulted in a strong response with tumor shrinkage and no disease ...

Researchers have created a groundbreaking antibody that combines targeting, delivery, and immune activation to treat cancer, ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...